NCT02637531 2022-04-04A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Infinity Pharmaceuticals, Inc.Phase 1 Unknown219 enrolled